Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prophylactic rituximab added to standard immunosuppression after kidney transplantation
NL-OMON30882Phase 2Not yet recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Aug 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial in kidney allograft rejection comparing Rituximab plus standard immunosuppression with Placebo plus standard immunosuppression (2 arms). Primary endpoints: Incidence of biopsy-confirmed acute rejection and Severity of biopsy-confirmed acute rejection. Planned start Aug 2007; status: not yet recruiting.
02
Drugs
rituximab
03
Conditions
kidney allograft rejection
Beyond the preview
Go deeper on NL-OMON30882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON30882.